Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.

Expert opinion on drug metabolism & toxicology - 1 Sept 2021

Hamilton Gerhard, Plangger Adelina

Abstract excerpt

INTRODUCTION: KRAS is the most frequently mutated oncogenic driver in pancreatic, lung, and colon cancer. Recently, KRAS inhibitors in clinical use show promising activity but most responses are partial and drug resistance develops. The use of therapeutics in combination with KRAS inhibitors are expected to improve outcomes. AREAS COVERED: This review describes the KRAS G12C mutation-specific inhibitors and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 34347509
DOI: 10.1080/17425255.2021.1965123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.PMID 34347509Read ↗

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell linesSemantic proximity Read ↗

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell linesSemantic proximity Read ↗

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.Semantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.Semantic proximity Read ↗

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRASG12C inhibitor: combing for combination.Semantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.